Published in final edited form as:

Bioorg Med Chem Lett. 2007 June 1; 17(11): 2979–2982.

Synthesis and biological evaluation of nitric oxide-releasing derivatives of oleanolic acid as inhibitors of HepG2 cell apoptosis

Li Chen^{a,b}, Yihua Zhang^{a,*}, Xiangwen Kong^a, Sixun Peng^a, and Jide Tian^{c,*}

a Center of Drug Discovery, China Pharmaceutical University, 24 Tongji Xiang, Nanjing 210009, P.R.China

b Department of Phytochemistry, China Pharmaceutical University, 1 Shennonglu, Nanjing 210038, P.R.China

c Department of Molecular & Medical Pharmacology, University of California Los Angeles, Los Angeles, CA 90095, USA

Abstract

A total of 106 nitric oxide-releasing derivatives of oleanolic acid were synthesized and their effects on the inhibition of anti-Fas-mediated HepG2 cell apoptosis were evaluated in vitro. Several compounds inhibited anti-Fas mediated HepG2 cell apoptosis in a dose-dependent manner. Within this series of compounds, **8b** is the most potent inhibitor. The development of new NO-releasing derivatives of oleanolic acid may aid in the design of NO-based medicines for the intervention of human liver inflammatory diseases.

Keywords

oleanolic acid; nitrate; NO-donors; biological evaluation; apoptosis

Nitric oxide (NO), synthesized from L-arginine by a family of constitutive and inducible NO synthases (cNOS and iNOS), is a small, diffusible, highly reactive molecule with dichotomous biological functions, such as blood vessel dilatation, neurotransmission, modulation of the hair cycle, and penile erections.¹ NO can also be generated from synthetic NO-releasing compounds, such as nitrate, furoxan, hydroxyguanidine, S-nitrosothiol, diazeniumdiolate, and others.² Higher concentrations of NO can promote the apoptosis of many types of cells, while lower concentrations of NO usually protect cells, such as hepatocytes, from inflammation-mediated apoptosis.³ Several mechanisms have been proposed to explain the anti-apoptosis effects of NO, including increased cGMP production, inhibition of caspase activation as well as prevention of mitochondrial permeability transition that leads to the release of cytochrome C into the cytosol.⁴

Increased scientific evidence indicates that NO deficiency is implicated in many physiological and pathological processes within the mammalian body. This fact provides a plausible biologic basis for the application of NO replacement therapy in clinic. However, the diverse bioactivities of NO limit its clinical application. New types of NO-releasing compounds/drug hybrids need to be developed for obtaining tissue-specific NO-related function.

*Corresponding authors^a, Tel: +86-25-86635503; fax: +86-25-86635503; e-mail: zyhtgd@hotmail.com or Tel: 310-206-3350; fax: 310-825-6267; e-mail: jtian@mednet.ucla.edu

Publisher's Disclaimer: This is a PDF file of an unedited manuscript that has been accepted for publication. As a service to our customers we are providing this early version of the manuscript. The manuscript will undergo copyediting, typesetting, and review of the resulting proof before it is published in its final citable form. Please note that during the production process errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.

Oleanolic acid (OA) is a triterpenoid compound, widely found in natural plants.⁵ Systemic treatment with the purified OA leads predominately to the distribution and metabolism of OA in the liver. OA has been shown to protect rodent liver from CCl₄ and many other toxicant-induced hepatotoxicity and chronic cirrhosis.⁶ Importantly, OA has been clinically used as a safe nonprescription drug for treatment of hepatitis in China for more than 20 years,⁷ although its therapeutic efficacy is limited. The therapeutic effect, the property of liver-specific metabolism, and wide availability make it to be an ideal base for the design of new NO-releasing compounds for the production of NO specifically in the liver. The combination of NO and OA probably provides synergic protection of hepatocytes from inflammation- and toxicant-mediated liver damage.

In the present studies, 106 novel NO-releasing derivatives of OA were synthesized by connecting NO-donating moiety to the OA-28-COOH/OA-3-OH through varying lengths of linkers. The various linkers containing anti-oxygen functionalities, such as ferulic acid, p-hydroxyl cinnamic acid and vanillic acid⁸ were designed to increase the ability of these objective compounds to scavenge free radicals. The bioactivities of all derivatives of OA were evaluated. Several compounds were found to inhibit anti-Fas mediated hepatocyte apoptosis and their anti-apoptotic effects were dose-dependent. One of the compounds, **8b**, inhibited hepatocyte apoptosis at a lower nanomolar level. The development of new NO-releasing derivatives of OA may aid in the design of NO-based new medicine for the intervention of human inflammatory liver diseases.

The synthetic routes of very important intermediates (**2a–2g**, **6a–6b**) are outlined in scheme 1. Ferulic acid (**1a**) or p-hydroxyl cinnamic acid (**1b**) was first treated with dibromoalkanes bearing 2 to 6 carbons in the presence of Et₃N and acetone at 50 °C to generate compounds **2a–2g** in 60–73% yields. In a similar way, compounds **6a** and **6b** were obtained in 61–65% yields by treatment of vanillic acid (**5**) with 1, 3-dibromopropane and 1, 4-dibromobutane, respectively.

The synthetic routes of OA-nitrate conjugates (**8a–8g**, **9a–9g** and **11a–11b**, **12a–12b**) are summarized in schemes 2 and 3. Several strategies were attempted to esterify OA-28-COOH directly with hydroxyl compounds, but failed, perhaps because of the large steric hindrance and weak acidity of OA-28-COOH. Alternatively, OA was first treated with trifluoroacetic anhydride to form a mixed anhydride in a quantitative yield after stirring at room temperature for 10 min. The resulting mixed anhydride was then reacted with hydroxyl compounds (**2a–2g** or **6a–6b**) in toluene to afford 3-O-trifluoroacetyl OA esters (**7a–7g** and **10a–10b**) in good yields (70–78%), respectively.^{9, 10} Compounds **7a–7g** or **10a–10b** were further converted to the corresponding nitrates **8a–8g** or **11a–11b** respectively with AgNO₃ in THF/CH₃CN. Compounds **9a–9g** or **12a–12b** were prepared by the hydrolysis of **8a–8g** or **11a–11b**, respectively, with diluted KHCO₃ to remove trifluoroacetyl group at C-3-OH without affecting other ester bonds. The resulting products were purified by column chromatography and their structures were characterized by IR, ¹HNMR, MS and elemental analysis.¹¹

Compounds **8a–8g**, **9a–9g**, **11a**, **11b**, **12a**, **12b** and controls, OA and NCX-1000, were *in vitro* evaluated for their protective effects on anti-Fas mediated HepG2 cell apoptosis determined by LDH assay.¹² As shown in Fig. 1, treatment with different concentrations of OA failed to protect the HepG2 cells from anti-Fas induced apoptosis as there was no significant difference in the percentage of survived HepG2 cells between the presence and absence of different concentrations of OA. Treatment with NCX-1000, a NO-releasing derivative of ursodeoxycholic acid (UDCA) generated by adding an ONO₂ moiety through an antioxidant spacer, showed moderate protective effects and NCX-1000 at 10^{−6} M protected 33.4% of HepG2 cells from anti-Fas induced apoptosis, consistent with previous report.³ Furthermore, five of the tested compounds displayed great protective effects, which were 10–1000 folds

stronger than that of NCX-1000. The lowest concentration that significantly inhibited anti-Fas induced HepG2 cell apoptosis was 10^{-10} M for **8b**, 10^{-9} M for **8c**, 10^{-8} M for **8f** or 10^{-7} M for **8d** and **8g**, respectively. A similar pattern of protective effects was observed when using the p53^{-/-} HepG2 cells, indicating that the protective effects of these NO-releasing derivatives of OA were independent of p53. Given that Fas/FasL-mediated hepatocyte apoptosis was involved many inflammatory- and toxicant-mediated liver diseases the potent anti-apoptotic effect of NO-releasing derivatives of OA suggests that these compounds may be potential for the treatment of inflammatory diseases in clinic.

As shown in Fig. 2, these compounds produced low levels of NO (about 12 ng/ml for **8b**, 12 ng/ml for **8c**, 21 ng/ml for **8d**, 18 ng/ml for **8f**, 20 ng/ml for **8g** and 28 ng/ml for **11b**, respectively) determined by *in vitro* Griess reaction. This is consistent with the notion that low dose of NO protects cells from inflammation-mediated apoptosis. Notably, some compounds that produced higher levels of NO *in vitro* showed potent cytotoxicity on human liver cancer cells (unpublished observations). In addition, our preliminary studies showed that oral treatment with **8b** at 128 mg.kg⁻¹ significantly inhibited CCl₄-induced hepatic fibrosis and liver damage in rats (data not shown). Collectively, NO-releasing derivatives of OA with low level of NO productivity protected human hepatocytes from anti-Fas mediated apoptosis.

Analysis of structure-activity relationships suggests that the A-ring of OA may be a good target for further modification as the compounds **8b**, **8c**, **8d**, **8f** and **8g**, whose C-3-OH of A-ring was connected with trifluoroacetyl, showed potent anti-apoptotic activities, while the compounds **9b**, **9c**, **9d**, **9f** and **9g** with corresponding free C-3-OH were inactive. Secondly, the length of the linkers connecting to ferulic acid or p-hydroxyl cinnamic acid appears crucial for their bioactivities. The **8b** with a 3-carbon long linker had 10–100 folds more potent anti-apoptotic activity than **8c** or **8d** respectively, while **8a** was inactive. Similarly, the compounds **8f** and **8g**, but not **8e**, had anti-apoptotic activity. Apparently, a 3-carbon long of linker was optimal while compounds with longer linkers were accompanied by decreased bioactivities. Furthermore, the potent anti-apoptotic activities were governed by appropriate anti-oxygen reagent, like ferulic acid, at the C-28 of OA esters as compounds **8b** and **8c** showed higher anti-apoptotic activities than the corresponding compounds **8f**, **8g** and **11a**, **11b**, even if they had the same length of carbon chain. Finally, these OA-nitrate conjugates at less than 10^{-6} M, but not OA, inhibited anti-Fas mediated HepG2 cell apoptosis in our experimental system, suggesting that the NO-releasing moieties may be responsible for the inhibitory activities of these derivatives of OA.

A series of OA-nitrate conjugates were synthesized and their biological functions were evaluated. Within the series of compounds, five of them showed to inhibit anti-Fas mediated hepatocyte apoptosis *in vitro* and their anti-apoptotic effects were dose-dependent. Notably, the compound **8b** was the most potent inhibitor and protected hepatocytes from anti-Fas mediated apoptosis at a lower nanomolar level. The preliminary SAR analysis of these compounds revealed that connection of the A-ring of OA with an optimal length of linker and the C-28 of OA esters with an anti-oxygen reagent was crucial for their anti-apoptotic activities. Together, these findings provide a new framework for the rational design of NO-based medicine for the intervention of human inflammatory liver diseases in clinic.

Acknowledgements

We thank Ms. Xiaochun Feng and Ms. Xiuying Chen for their technical supports in some biological assays. This study was partially supported by grant from the National Institute of Health (NIH) (CA116846, Jide Tian).

References and notes

1. Grisham MB, Jourdeuil D, Wink DA. Am J Physiol 1999;276:G315. [PubMed: 9950804]

2. (a) Hou YC, Janczuk A, Wang PG. *Curr Pharm Des* 1999;5:417. [PubMed: 10390607] (b) Wang PG, Xian M, Tang X, Wu X, Wen Z, Cai T, Janczuk AJ. *Chem Rev* 2002;102:1091. [PubMed: 11942788]
3. (a) Fiorucci S, Mencarelli A, Palazzetti B, Del Soldato P, Morelli A, Ignaro LJ. *Proc Natl Acad Sci* 2001;98:2652. [PubMed: 11226294] (b) Ebisawa Y, Kono T, Yoneda M, Asama T, Chisato N, Sugawara M, Ishikawa K, Iwamoto J, Ayabe T, Kasai S. *J Surg Res* 2004;118:183. [PubMed: 15100007] (c) Jenkins DC, Charles LL, Thomsen DW, Moss DW, Holmes LS, Baylis SA, Rhode P, Westmore K, Emson PC, Moncada S. *Proc Natl Acad Sci* 1995;92:4392. [PubMed: 7538668]
4. Moncada S, Erusalimsky JD. *Nat Rev Mol Cell Biol* 2002;3:214. [PubMed: 11994742]
5. Liu J. *J Ethnopharmacol* 1995;49:57. [PubMed: 8847885]
6. (a) Liu Y, Hartley DP, Liu J. *Toxicol Lett* 1998;95:77. [PubMed: 9635410] (b) Han DW, Ma XH, Zhao YC, Yin L, Ji CX. *J Tradit Chin Med* 1982;2:83. [PubMed: 6765707] (c) Liu J, Liu Y, Madhu C, Klaassen CD. *J Pharmacol Exp Ther* 1993;266:1607. [PubMed: 8371159] (d) Liu Y, Kreppel H, Liu J, Choudhuri S, Klaassen CD. *J Pharmacol Exp Ther* 1993;266:400. [PubMed: 8331568]
7. (a) Liu J, Liu Y, Parkinson A. *J Pharmacol Exp Ther* 1995;275:768. [PubMed: 7473165] (b) Wang LX, Han GX, Liu WY. *J Pharm Practice* 2001;19:104.
8. (a) Ozaki Y. *Chem Pharm Bull* 1992;40:954. [PubMed: 1525949] (b) Hu HJ, Hang BQ. *J China Pharm Univ* 1990;21:279. (c) Lin YH, Chen WW. *Acta Pharm Sin* 1994;28:267.
9. (a) Parish RC, Stock LM. *Tetra Lett* 1964;20:1285. (b) Bourne JE, Stacey M, Tatlow JC, Tedder JM. *J Chem Soc* 1949:2976.
10. Chen L. *Ph. D. dissertation*. China Pharmaceutical University at Nanjing in China, **2004**
11. Analytical data for **8b**: mp 112~114°C IR (KBr, cm⁻¹) : 1779, 1750, 1715, 1635 ; ¹H-NMR (CDCl₃, 300MHz): δ 0.86 (s, 3H, CH₃), 0.92 (s, 6H, 2×CH₃), 0.94 (s, 3H, CH₃), 0.97 (s, 6H, 2×CH₃), 1.19 (s, 3H, CH₃), 2.10~2.18 (m, 2H, CH₂), 2.94~3.00 (m, 1H, C₁₈-H), 3.83 (s, 3H, OCH₃), 4.32 (t, 2H, OCH₂, J=6.0Hz), 4.61 (t, 2H, OCH₂, J=6.0Hz), 4.68~4.73 (m, 1H, H-3α), 5.33 (brs, 1H, H-12), 6.36 (d, 1H, =CH, J=16.0Hz), 6.95~6.97 (m, 1H, Ar-H), 7.07~7.12 (m, 2H, Ar-H), 7.65 (d, 1H, =CH, J=16.0Hz); ESI-MS: 854 [M+Na]⁺; Anal. C₄₅H₆₀F₃NO₁₀ Found: (%) N 1.56 C 65.34 H 7.31 Calcd: (%) N 1.68 C 64.79 H 7.27. Analytical data for **9b**: mp 98 ~ 100°C; IR (KBr, cm⁻¹) : 3523, 1748, 1715, 1634 ; ¹H-NMR (CDCl₃, 300MHz): δ (ppm): 0.82 (s, 3H, CH₃), 0.88 (s, 3H, CH₃), 0.95 (s, 3H, CH₃), 0.97 (s, 3H, CH₃), 1.00 (s, 3H, CH₃), 1.03 (s, 3H, CH₃), 1.23 (s, 3H, CH₃), 2.96~3.02 (m, 1H, H-18), 3.25 (brs, 1H, H-3α), 3.85 (s, 3H, OCH₃), 4.35 (t, 2H, OCH₂, J=6Hz), 4.64 (t, 2H, OCH₂, J=6.0Hz), 5.36 (brs, 1H, C₁₂-H), 6.38 (d, 1H, =CH, J=16.0Hz), 6.99 (d, 1H, ArH, J=7.8Hz), 7.11~7.16 (m, 2H, ArH), 7.68 (d, 1H, =CH, J=16.0Hz) ; ESI-MS : 758 [M+Na]⁺ ; Anal. C₄₃H₆₁NO₉·0.5H₂O Found : (%) N 1.64 C 69.34 H 8.52 Calcd : (%) N 1.88 C 69.31 H 8.32. Analytical data for **11b**: mp 64 ~ 66°C IR (KBr, cm⁻¹) : 1779, 1756, 1720, 1632; ¹H-NMR (CDCl₃, 300MHz): δ 0.85 (s, 3H, CH₃), 0.92 (s, 6H, 2×CH₃), 0.94 (s, 3H, CH₃), 0.97 (s, 6H, 2×CH₃), 1.19 (s, 3H, CH₃), 2.94~3.00 (m, 1H, H-18), 3.85 (s, 3H, OCH₃), 4.36 (brs, 2H, OCH₂), 4.53 (brs, 2H, OCH₂), 4.68~4.73 (m, 1H, 3α-H), 5.33 (brs, 1H, C₁₂-H), 7.00 (d, 1H, ArH, J = 7.9Hz), 7.61~7.64 (m, 2H, ArH) ; ESI-MS : 823 [M+NH₄]⁺, 828 [M+Na]⁺; Anal. C₄₄H₆₀F₃NO₁₀ Found: (%) N 1.62 C 64.16 H 7.45 Calcd: (%) N 1.71 C 64.45 H 7.38.
12. Fernandez-Cruz E, Escartin P, Bootello A, Kreisler M, Segovia de Arana JM. *Clin Exp Immunol* 1978;31:436. [PubMed: 657588]

Fig 1.

NO-releasing derivatives of OA protected hepatocytes from anti-Fas mediated apoptosis. The anti-apoptotic effects of NO-releasing derivatives of OA were evaluated by LDH assays. Briefly, HepG2 cells at 10^4 /well were plated in triplicate in 96-well plates in 4% FCS and 2 μ g/ml cycloheximide in Phenol-red free DMEM. The cells were treated with anti-Fas (50 ng/ml for CH-11 or 1.5 μ g/ml for DX2) in the presence or absence of indicated concentrations of OA, NCX-1000, or NO-releasing derivatives of OA at 37°C 5% CO₂ for 18 h. Unmanipulated cells or the cells treated with 1% triton X-100 were used as negative or positive controls for cytotoxicity. Their supernatants were harvested and their contained LDH activities were measured by LDH assays using the LDH cytotoxicity detection kit (Roche) and following the manufactory's instructions at O.D. (490/650). The protective effect (%) was determined by the formula: the protective effect (%) = $(1 - (\text{O.D experiments} - \text{O.D negative controls}) / (\text{O.D positive controls} - \text{O.D negative controls})) \times 100$. Data present as the mean of three independent experiments and the O.D values of intra-group variations were less than 10%.

Fig 2.

NO-releasing derivatives of OA produced low levels of NO *in vitro*. NO_2^- concentrations which represent the quantity of NO were determined by Griess assay. Griess reagent could combine with NO_2^- and form the chromophore after 10 min at 30° , the absorbance then was measured at 540nm.

Scheme 1.

Reagents and conditions: (i) Br(CH₂)_nBr, Et₃N, 50 °C, 4h (60–73%); (ii) AgOH, NaOH (65%); (iii) HCl; (iv) Br(CH₂)_nBr (n=3 or 4), Et₃N, 50 °C, 4h (61–65%).

Scheme 2.

Reagents and conditions: (i) (CF₃CO)₂O, **2a–2g**, <90°C, 6h (70–78%); (ii) THF/CH₃CN, AgNO₃, reflux (67–75%); (iii) KHCO₃, r.t. (90–95%)

Scheme 3.

Reagents and conditions: (i) $(\text{CF}_3\text{CO})_2\text{O}$, **6a–6b**, $<90^\circ\text{C}$, 6h (71–73%); (ii) THF/ CH_3CN , AgNO_3 , reflux (67–73%); (iii) KHCO_3 , r.t. (90–95%).